Prospective Evaluation of Immune Activation Associated with Response                     to Radioembolization Assessed with PET/CT in Women with Breast Cancer Liver                     Metastasis

Deipolyi, Amy R.; Johnson, Christopher; Riedl, Christopher C.; Kunin, Henry; Solomon, Stephen B.; Öklü, Rahmi; Hsu, Meier; Moskowitz, Chaya S.; Kombak, Faruk Erdem; Bhanot, Umesh; Erinjeri, Joseph P.

doi:10.1148/radiol.220158

Cited by 11 publications

(5 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…They did decrease in these populations at 3 and 6 months, leading the authors to suggest that perhaps the introduction of checkpoint inhibitors may prolong the favorable immune environment. Finally, a study of 23 patients receiving TARE for metastatic breast cancer showed that increased frequency of baseline PD-1 expression by CD4+ TILs in the tumor microenvironment was associated with clinical response [99]. While this study is in a different cancer population than HCC, it does provide some further reason to be optimistic about the underlying scientific principle.…”

Section: Transarterial Radioembolizationmentioning

confidence: 86%

Friend or Foe? Locoregional Therapies and Immunotherapies in the Current Hepatocellular Treatment Landscape

Young

Hannallah

Goldberg

et al. 2023

IJMS

View full text Add to dashboard Cite

Over the last several decades, a number of new treatment options for patients with hepatocellular carcinoma (HCC) have been developed. While treatment decisions for some patients remain clear cut, a large numbers of patients have multiple treatment options, and it can be hard for multidisciplinary teams to come to unanimous decisions on which treatment strategy or sequence of treatments is best. This article reviews the available data with regard to two treatment strategies, immunotherapies and locoregional therapies, with a focus on the potential of locoregional therapies to be combined with checkpoint inhibitors to improve outcomes in patients with locally advanced HCC. In this review, the available data on the immunomodulatory effects of locoregional therapies is discussed along with available clinical data on outcomes when the two strategies are combined.

show abstract

Section: Transarterial Radioembolizationmentioning

confidence: 86%

Friend or Foe? Locoregional Therapies and Immunotherapies in the Current Hepatocellular Treatment Landscape

Young

Hannallah

Goldberg

et al. 2023

IJMS

View full text Add to dashboard Cite

show abstract

“… 10 , 11 TARE has been shown to increase peripheral interleukin, intratumoral lymphocyte activation gene 3-positive CD4 + tumor-infiltrating lymphocytes, CD3 + T cells, regulatory T cells, and inflammatory (PD-L1+ and HLA-DR+) monocytes, suggesting a potential synergistic effect when combined with immune checkpoint inhibitors. 12 , 13 This study provides preliminary data on the radiological response of Y90 and Atezo/Bev treatment, given that target tumor control was achieved in all cases with the intention to treat (9/9) rather than palliative intent (n = 1). Among 4 patients with stage B tumor burden, 3 (75%) were downstaged to within Milan criteria.…”

Section: Discussionmentioning

confidence: 97%

Combination of transarterial radioembolization with atezolizumab and bevacizumab for intermediate and advanced staged hepatocellular carcinoma: A preliminary report of safety and feasibility

Yu,

Wang,

Ungchusri

et al. 2023

Journal of Interventional Medicine

View full text Add to dashboard Cite

“…It has been reported that the role of PD1 expression was complicated in diseases. For example, Deipolyi et al revealed that breast cancer patients with more PD1+ tumor‐infiltrating lymphocytes tended to achieve CR 38 . However, the relationship between PD1 expression and poor prognosis was also found 39 .…”

Section: Discussionmentioning

confidence: 99%

“…For example, Deipolyi et al revealed that breast cancer patients with more PD1+ tumor‐infiltrating lymphocytes tended to achieve CR. 38 However, the relationship between PD1 expression and poor prognosis was also found. 39 The analysis of CR rate only assessed the patients whether achived CR after the first course of the chemotherapy, but the prognosis was affected by many factors, including drug resistance and severity of disease, not only treatment response.…”

Section: Discussionmentioning

confidence: 99%

Immune checkpoint‐related gene polymorphisms are associated with acute myeloid leukemia

Wu,

Li,

Meng

et al. 2023

Cancer Medicine

View full text Add to dashboard Cite

BackgroundChemotherapy is still the standard regimen for treating acute myeloid leukemia (AML) and its disappointing efficacy requires the urgent need for new therapeutic targets. It is well known that immune response plays an increasingly significant role in the pathogenesis of AML.MethodsWe detected nine single nucleotide polymorphisms (SNPs) in immune checkpoint‐related genes, including PD1, LAG3, TIM3, and TIGIT in 285 AML inpatients and 324 healthy controls. SNP genotyping was performed on the MassARRAY platform. Furthermore, we analyzed the relationship between the susceptibility and prognosis of AML and the selected SNPs.ResultsOur results showed that rs2227982 and rs10204525 in PD1 were significantly associated with susceptibility to AML after false discovery rate correction. PD1 rs10204525 also showed a significant correlation with the response to chemotherapy and risk stratification of AML. Importantly, the AA genotype of PD1 (rs2227982) under the recessive model showed a negative impact on AML prognosis independently.ConclusionsOur results indicate that PD1 SNPs are important for susceptibility and prognosis in AML, which may provide a new therapeutic target for AML patients.

show abstract

Prospective Evaluation of Immune Activation Associated with Response to Radioembolization Assessed with PET/CT in Women with Breast Cancer Liver Metastasis

Cited by 11 publications

References 35 publications

Friend or Foe? Locoregional Therapies and Immunotherapies in the Current Hepatocellular Treatment Landscape

Friend or Foe? Locoregional Therapies and Immunotherapies in the Current Hepatocellular Treatment Landscape

Combination of transarterial radioembolization with atezolizumab and bevacizumab for intermediate and advanced staged hepatocellular carcinoma: A preliminary report of safety and feasibility

Immune checkpoint‐related gene polymorphisms are associated with acute myeloid leukemia

Contact Info

Product

Resources

About